Major institutional investors have begun pulling back from artificial intelligence drug discovery startups, citing intense frustration that curing complex human diseases cannot be reliably achieved within a standard fiscal quarter.
Despite pouring billions into companies promising to revolutionize the pharmaceutical lab with generative AI, Wall Street analysts reported Tuesday that they are increasingly losing patience with the sector. Several major funds have slashed their price targets for AI biotech firms after learning that generating a novel molecule still requires years of physical clinical trials rather than a simple overnight software deployment.
The sell-off was triggered by a series of disappointing earnings calls in which biotech executives admitted they could not simply push a beta version of a new liver disease treatment to patients to test for fatal bugs in real-time.
We were promised a complete disruption of the cellular paradigm, but these management teams are telling us we have to sit around waiting for Phase II human efficacy data.
In a research note circulated Monday, analysts at Morgan Stanley warned that the basic laws of human metabolics represent a significant headwind to shareholder value. The note urged AI drug founders to consider pivoting away from the low-margin, time-intensive business of extending human life, suggesting they instead retrain their proprietary models to generate targeted pharmaceutical marketing copy.
By the close of trading, shares in leading AI biotech firm Recursion Pharmaceuticals had fallen 14 percent after its board formally rejected an activist investor’s proposal to bypass the FDA and launch its experimental Alzheimer’s treatment as a monthly subscription app.